Delivery Order SPE2DB22D1106-SPE2DB25FEQX2
- Not listed
- The Defense Logistics Agency awarded a $1,768.44 delivery order to AmerisourceBergen Drug Corp for XCOPRI 50 mg tablets (30-count supply) under a firm fixed price contract type. The award was issued on June 2, 2025, with an ultimate completion date of June 3, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, performed the work at its corporate office location. This delivery order is a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $1,874.46 to AmerisourceBergen Drug Corp for XCOPRI 50 mg tablets (30-count supply) under a firm fixed-price contract. The award was made on September 17, 2025, with an ultimate completion date of September 18, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $1,877.45 delivery order to AmerisourceBergen Drug Corp for XCOPRI 200 mg tablets (30-count units) on June 16, 2025, with a completion date of June 17, 2025. This firm fixed-price, competitively awarded delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $3,219.60 to AmerisourceBergen Drug Corp for XCOPRI 50 mg tablets (30-count units) with an ultimate completion date of August 28, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor headquartered in Conshohocken, Pennsylvania. The contract represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XCOPRI 100 mg tablets (30-count) on May 20, 2025, with a ceiling value of $1,979.46 under a firm fixed-price contract type. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award was made through open competition with no set-aside designation,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XCOPRI 50 mg tablets (30-count) with a ceiling value of $1,786.08. This firm fixed-price delivery order, issued on April 24, 2025, with a completion date of April 25, 2025, was competitively awarded without set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under the company's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $3,536.88 to AmerisourceBergen Drug Corp for XCOPRI 200 mg tablets (30-count units) under a firm fixed price contract. The award was made on July 30, 2025, with a completion date of July 31, 2025, and performance will be executed at the vendor's corporate office in Conshohocken, Pennsylvania. This delivery order was competitively awarded without set-aside designation, reflecting the vendor's established capability to meet federal...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,794.10 to AmerisourceBergen Drug Corp for XCOPRI 150 mg tablets (30-count supply) on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion global pharmaceutical support vehicle running...
- The Defense Logistics Agency awarded a $1,497.58 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XCOPRI 50 mg tablets (30-count units) on July 24, 2025, with an ultimate completion date of July 25, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a delivery order valued at $1,178.96 to AmerisourceBergen Drug Corp for XCOPRI 25 mg tablets (30-count package). The contract, issued on September 8, 2025, with an ultimate completion date of September 9, 2025, represents a firm fixed-price delivery order with no set-aside designation. The work will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FEQX2Delivery Order
The Defense Logistics Agency awarded a $3,536.88 delivery order to AmerisourceBergen Drug Corp for XCOPRI 25 mg tablets (30-count units) with a firm fixed price structure. The contract, which was competitively awarded without set-aside designation, is scheduled for completion by June 2, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, supplies a comprehensive portfolio of brand-name and generic medications to federal medical procurement programs, with a particular focus on military and veteran healthcare systems. The parent IDC vehicle enables the company to fulfill diverse pharmaceutical needs across multiple therapeutic domains for customers including the Defense Health Agency and U.S. Coast Guard. This specific delivery order for XCOPRI, a medication used in neurological treatment, exemplifies the company's role as a critical vendor in DLA's pharmaceutical supply chain and reflects the ongoing demand for specialized medical commodities within the military healthcare system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.5k | 5/30/25 |